Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 115

1.

Comparative effectiveness of teriflunomide vs dimethyl fumarate in multiple sclerosis.

Laplaud DA, Casey R, Barbin L, Debouverie M, De Sèze J, Brassat D, Wiertlewski S, Brochet B, Pelletier J, Vermersch P, Edan G, Lebrun-Frenay C, Clavelou P, Thouvenot E, Camdessanché JP, Tourbah A, Stankoff B, Al Khedr A, Cabre P, Lubetzki C, Papeix C, Berger E, Heinzlef O, Debroucker T, Moreau T, Gout O, Bourre B, Wahab A, Labauge P, Magy L, Defer G, Guennoc AM, Maubeuge N, Labeyrie C, Patry I, Nifle C, Casez O, Michel L, Rollot F, Leray E, Vukusic S, Foucher Y; SFSEP and OFSEP groups.

Neurology. 2019 Aug 13;93(7):e635-e646. doi: 10.1212/WNL.0000000000007938. Epub 2019 Jul 12.

PMID:
31300547
2.

Frequency and characteristics of short versus longitudinally extensive myelitis in adults with MOG antibodies: A retrospective multicentric study.

Ciron J, Cobo-Calvo A, Audoin B, Bourre B, Brassat D, Cohen M, Collongues N, Deschamps R, Durand-Dubief F, Laplaud D, Maillart E, Papeix C, Zephir H, Bereau M, Brochet B, Carra-Dallière C, Derache N, Gagou-Scherer C, Henry C, Kerschen P, Mathey G, Maubeuge N, Maurousset A, Montcuquet A, Moreau T, Prat C, Taithe F, Thouvenot E, Tourbah A, Rollot F, Vukusic S, Marignier R.

Mult Scler. 2019 May 31:1352458519849511. doi: 10.1177/1352458519849511. [Epub ahead of print]

PMID:
31148523
3.

Anxiety and depression in patients with multiple sclerosis: The mediating effects of perceived social support.

Henry A, Tourbah A, Camus G, Deschamps R, Mailhan L, Castex C, Gout O, Montreuil M.

Mult Scler Relat Disord. 2019 Jan;27:46-51. doi: 10.1016/j.msard.2018.09.039. Epub 2018 Oct 2.

PMID:
30317070
4.

Co-occurrence of MS and ALS: a clue in favor of common pathophysiological findings?

Guennoc AM, Pallix-Guyot M, Le Page E, Le Port D, Daryabin M, Hergesheimer R, Beltran S, Tourbah A, Edan G, Corcia P.

Amyotroph Lateral Scler Frontotemporal Degener. 2018 Nov;19(7-8):500-505. doi: 10.1080/21678421.2018.1476547. Epub 2018 Sep 3.

PMID:
30175630
5.

MD1003 (High-Dose Pharmaceutical-Grade Biotin) for the Treatment of Chronic Visual Loss Related to Optic Neuritis in Multiple Sclerosis: A Randomized, Double-Blind, Placebo-Controlled Study.

Tourbah A, Gout O, Vighetto A, Deburghgraeve V, Pelletier J, Papeix C, Lebrun-Frenay C, Labauge P, Brassat D, Toosy A, Laplaud DA, Outteryck O, Moreau T, Debouverie M, Clavelou P, Heinzlef O, De Sèze J, Defer G, Sedel F, Arndt C.

CNS Drugs. 2018 Jul;32(7):661-672. doi: 10.1007/s40263-018-0528-2.

6.

Clinical spectrum and prognostic value of CNS MOG autoimmunity in adults: The MOGADOR study.

Cobo-Calvo A, Ruiz A, Maillart E, Audoin B, Zephir H, Bourre B, Ciron J, Collongues N, Brassat D, Cotton F, Papeix C, Durand-Dubief F, Laplaud D, Deschamps R, Cohen M, Biotti D, Ayrignac X, Tilikete C, Thouvenot E, Brochet B, Dulau C, Moreau T, Tourbah A, Lebranchu P, Michel L, Lebrun-Frenay C, Montcuquet A, Mathey G, Debouverie M, Pelletier J, Labauge P, Derache N, Coustans M, Rollot F, De Seze J, Vukusic S, Marignier R; OFSEP and NOMADMUS Study Group.

Neurology. 2018 May 22;90(21):e1858-e1869. doi: 10.1212/WNL.0000000000005560. Epub 2018 Apr 25.

PMID:
29695592
7.

Letter to the Editors - Multiple sclerosis and related disorders - Birnbaum et al., 2017.

Tourbah A, Sedel F.

Mult Scler Relat Disord. 2018 Feb;20:204. doi: 10.1016/j.msard.2018.01.028. Epub 2018 Feb 1. No abstract available.

PMID:
29414300
8.

Treating asymptomatic bacteriuria before immunosuppressive therapy during multiple sclerosis: Should we do it?

Rouzaud C, Hautecoeur P, Donze C, Heinzlef O, Dinh A; Club Francophone de la Sclérose en Plaque, Creange A, Abdullatif A, Audouin B, Tourbah A, Berger E, Bourre B, Brochet B, Mekies C, Cabre P, Papeix C, Casez O, Brassat D, Defer G, Derache N, De Seze J, Dive D, LePage E, Fromont A, Gouider R, Edan G, Pelletier J, Grimaud J, Guennoc AM, Camdessanché JP, Kwiatkowski A, Laplaud D, Lebrun C, Debouverie M, Coustans M, Gout O, La Rochelle OA, Heinzlef O, Ouallet JC, Cavelou P, Hautecoeur P, Labauge P, Vermersch P, Wiertlewski S, Vukusic S, Marignier R, Schluep M, Seeldrayers P, Slassi I, Stankoff B, Thaite F, Moreau T, Thouvenot E, Zephir H, Ciron J, Collongues N, Kerschen P, Cohen M, Gueguen A, Mathey G, Carra C, Bernady P, Faucheux JM, Planque E, Donze C, Ruet A, Mouzawakh C, Pittion S.

Mult Scler Relat Disord. 2017 Nov;18:161-163. doi: 10.1016/j.msard.2017.08.009. Epub 2017 Aug 24. No abstract available.

PMID:
29141801
9.

Cognition and quality of life in clinically isolated syndrome patients starting a disease modifying therapy in the QUALICIS study may not predict treatment response at one year.

Cohen M, Brochet B, Clavelou P, Le Page E, Vermersch P, Tourbah A, Moreau T, Joly H, Sakarovitch C, Lebrun C; Qualicis Study Group.

J Neurol Sci. 2017 Nov 15;382:73-78. doi: 10.1016/j.jns.2017.09.030. Epub 2017 Sep 22.

PMID:
29111024
10.

USPIO-positive MS lesions are associated with greater tissue damage than gadolinium-positive-only lesions during 3-year follow-up.

Kerbrat A, Combès B, Commowick O, Maarouf A, Bannier E, Ferré JC, Tourbah A, Ranjeva JP, Barillot C, Edan G.

Mult Scler. 2017 Oct 1:1352458517736148. doi: 10.1177/1352458517736148. [Epub ahead of print]

PMID:
29064775
11.

Matrix metalloproteinase 9 is decreased in natalizumab-treated multiple sclerosis patients at risk for progressive multifocal leukoencephalopathy.

Fissolo N, Pignolet B, Matute-Blanch C, Triviño JC, Miró B, Mota M, Perez-Hoyos S, Sanchez A, Vermersch P, Ruet A, de Sèze J, Labauge P, Vukusic S, Papeix C, Almoyna L, Tourbah A, Clavelou P, Moreau T, Pelletier J, Lebrun-Frenay C, Montalban X, Brassat D, Comabella M; Biomarkers and Response to Natalizumab for Multiple Sclerosis Treatment (BIONAT), Best EScalation Treatment in Multiple Sclerosis (BEST-MS), and the Société Francophone de la Sclérose En Plaques (SFSEP) Network.

Ann Neurol. 2017 Aug;82(2):186-195. doi: 10.1002/ana.24987. Epub 2017 Jul 22.

PMID:
28681388
12.

Social Cognition Abilities in Patients With Different Multiple Sclerosis Subtypes.

Henry A, Tourbah A, Chaunu MP, Bakchine S, Montreuil M.

J Int Neuropsychol Soc. 2017 Sep;23(8):653-664. doi: 10.1017/S1355617717000510. Epub 2017 Jun 28.

PMID:
28656885
13.

Natalizumab-PML survivors with subsequent MS treatment: Clinico-radiologic outcome.

Maillart E, Vidal JS, Brassat D, Stankoff B, Fromont A, de Sèze J, Taithe F, Clavelou P, Bourre B, Delvaux V, Rico A, Labauge P, Tourbah A, Lebrun C, Pelletier J, Moreau T, Louapre C, Lubetzki C, Papeix C.

Neurol Neuroimmunol Neuroinflamm. 2017 Apr 14;4(3):e346. doi: 10.1212/NXI.0000000000000346. eCollection 2017 May.

14.

Reply to the letter: Biotinidase deficiency masquerading as multiple sclerosis?

Tourbah A, Sedel F.

Mult Scler. 2018 Feb;24(2):239. doi: 10.1177/1352458517702554. Epub 2017 Mar 24. No abstract available.

PMID:
28337934
15.

Theoretical modeling of time-dependent skin temperature and heat losses during whole-body cryotherapy: A pilot study.

Polidori G, Marreiro A, Pron H, Lestriez P, Boyer FC, Quinart H, Tourbah A, Taïar R.

Med Hypotheses. 2016 Nov;96:11-15. doi: 10.1016/j.mehy.2016.09.019. Epub 2016 Sep 23.

PMID:
27959267
16.

Reply to Letter to the Editor: Biotin supplementation in MS clinically valuable but can alter multiple blood test results by Siddiqui U, et al.

Tourbah A, Sedel F.

Mult Scler. 2017 Apr;23(4):620-621. doi: 10.1177/1352458516680752. Epub 2016 Dec 7. No abstract available.

PMID:
27899553
17.

CD62L test at 2 years of natalizumab predicts progressive multifocal leukoencephalopathy.

Pignolet B, Schwab N, Schneider-Hohendorf T, Bucciarelli F, Biotti D, Averseng-Peaureaux D, Outteryck O, Ongagna JC, de Sèze J, Brochet B, Ouallet JC, Debouverie M, Pittion S, Defer G, Derache N, Hautecoeur P, Tourbah A, Labauge P, Castelnovo G, Clavelou P, Berger E, Pelletier J, Rico A, Zéphir H, Laplaud D, Wiertlewski S, Camu W, Thouvenot E, Casez O, Moreau T, Fromont A, Vukusic S, Papeix C, Vermersch P, Comabella M, Lebrun-Frenay C, Wiendl H, Brassat D; BIONAT, SFSEP, and BEST-MS networks.

Neurology. 2016 Dec 6;87(23):2491-2494. Epub 2016 Nov 4. No abstract available.

PMID:
27815407
18.

Targeting demyelination and virtual hypoxia with high-dose biotin as a treatment for progressive multiple sclerosis.

Sedel F, Bernard D, Mock DM, Tourbah A.

Neuropharmacology. 2016 Nov;110(Pt B):644-653. doi: 10.1016/j.neuropharm.2015.08.028. Epub 2015 Sep 5. Review.

19.

MD1003 (high-dose biotin) for the treatment of progressive multiple sclerosis: A randomised, double-blind, placebo-controlled study.

Tourbah A, Lebrun-Frenay C, Edan G, Clanet M, Papeix C, Vukusic S, De Sèze J, Debouverie M, Gout O, Clavelou P, Defer G, Laplaud DA, Moreau T, Labauge P, Brochet B, Sedel F, Pelletier J; MS-SPI study group.

Mult Scler. 2016 Nov;22(13):1719-1731. Epub 2016 Sep 1.

20.

Efficacy and safety profile of memantine in patients with cognitive impairment in multiple sclerosis: A randomized, placebo-controlled study.

Peyro Saint Paul L, Creveuil C, Heinzlef O, De Seze J, Vermersch P, Castelnovo G, Cabre P, Debouverie M, Brochet B, Dupuy B, Lebiez P, Sartori É, Clavelou P, Brassat D, Lebrun-Frenay C, Daplaud D, Pelletier J, Coman I, Hautecoeur P, Tourbah A, Defer G.

J Neurol Sci. 2016 Apr 15;363:69-76. doi: 10.1016/j.jns.2016.02.012. Epub 2016 Feb 6.

PMID:
27000224
21.

Normalisation of brain spectroscopy findings in Niemann-Pick disease type C patients treated with miglustat.

Sedel F, Chabrol B, Audoin B, Kaphan E, Tranchant C, Burzykowski T, Tourbah A, Vanier MT, Galanaud D.

J Neurol. 2016 May;263(5):927-936. doi: 10.1007/s00415-016-8051-1. Epub 2016 Mar 16.

22.

Comparative efficacy of fingolimod vs natalizumab: A French multicenter observational study.

Barbin L, Rousseau C, Jousset N, Casey R, Debouverie M, Vukusic S, De Sèze J, Brassat D, Wiertlewski S, Brochet B, Pelletier J, Vermersch P, Edan G, Lebrun-Frenay C, Clavelou P, Thouvenot E, Camdessanché JP, Tourbah A, Stankoff B, Al Khedr A, Cabre P, Papeix C, Berger E, Heinzlef O, Debroucker T, Moreau T, Gout O, Bourre B, Créange A, Labauge P, Magy L, Defer G, Foucher Y, Laplaud DA; CFSEP and OFSEP groups.

Neurology. 2016 Feb 23;86(8):771-8. doi: 10.1212/WNL.0000000000002395. Epub 2016 Jan 29.

23.

[Which prognostic criteria in multiple sclerosis?]

Tourbah A.

Rev Prat. 2016 Jan;66(1):40-42. French. No abstract available.

PMID:
30512397
24.

Ultra-small superparamagnetic iron oxide enhancement is associated with higher loss of brain tissue structure in clinically isolated syndrome.

Maarouf A, Ferré JC, Zaaraoui W, Le Troter A, Bannier E, Berry I, Guye M, Pierot L, Barillot C, Pelletier J, Tourbah A, Edan G, Audoin B, Ranjeva JP.

Mult Scler. 2016 Jul;22(8):1032-9. doi: 10.1177/1352458515607649. Epub 2015 Oct 9.

25.

The neuronal component of gray matter damage in multiple sclerosis: A [(11) C]flumazenil positron emission tomography study.

Freeman L, Garcia-Lorenzo D, Bottin L, Leroy C, Louapre C, Bodini B, Papeix C, Assouad R, Granger B, Tourbah A, Dollé F, Lubetzki C, Bottlaender M, Stankoff B.

Ann Neurol. 2015 Oct;78(4):554-67. doi: 10.1002/ana.24468. Epub 2015 Aug 21.

PMID:
26292991
26.

Biotin and demyelinating diseases--a new connection?

Tourbah A.

Mult Scler. 2015 Oct;21(12):1608-9. doi: 10.1177/1352458515599077. Epub 2015 Jul 30. No abstract available.

PMID:
26227004
27.

High doses of biotin in chronic progressive multiple sclerosis: a pilot study.

Sedel F, Papeix C, Bellanger A, Touitou V, Lebrun-Frenay C, Galanaud D, Gout O, Lyon-Caen O, Tourbah A.

Mult Scler Relat Disord. 2015 Mar;4(2):159-69. doi: 10.1016/j.msard.2015.01.005. Epub 2015 Jan 24.

28.

Criteria improving multiple sclerosis diagnosis at the first MRI.

Caucheteux N, Maarouf A, Genevray M, Leray E, Deschamps R, Chaunu MP, Daelman L, Ferré JC, Gout O, Pelletier J, Pierot L, Edan G, Tourbah A.

J Neurol. 2015;262(4):979-87. doi: 10.1007/s00415-015-7668-9. Epub 2015 Feb 17.

PMID:
25683762
29.

Clinical and MRI characterization of MS patients with a pure and severe cognitive onset.

Assouad R, Louapre C, Tourbah A, Papeix C, Galanaud D, Lubetzki C, Stankoff B.

Clin Neurol Neurosurg. 2014 Nov;126:55-63. doi: 10.1016/j.clineuro.2014.08.018. Epub 2014 Aug 20.

PMID:
25215443
30.

[Eight and a half plus syndrome as a first presentation of multiple sclerosis].

Wanono R, Daelman L, Maarouf A, Caucheteux N, Chaunu MP, Tourbah A.

Rev Neurol (Paris). 2014 Aug-Sep;170(8-9):553-4. doi: 10.1016/j.neurol.2014.03.013. Epub 2014 Jun 10. French. No abstract available.

PMID:
24924476
31.

Progressive neuropsychiatric manifestations of phenylketonuria in adulthood.

Daelman L, Sedel F, Tourbah A.

Rev Neurol (Paris). 2014 Apr;170(4):280-7. doi: 10.1016/j.neurol.2013.09.012. Epub 2014 Apr 13.

PMID:
24726436
32.

[Chronic meningoencephalitis with dementia].

Daelman L, Garcia T, Servettaz A, Tourbah A.

Rev Neurol (Paris). 2014 Jun-Jul;170(6-7):465-7. doi: 10.1016/j.neurol.2014.02.005. Epub 2014 Apr 13. French. No abstract available.

PMID:
24726435
33.

Predictive value of imaging markers at multiple sclerosis disease onset based on gadolinium- and USPIO-enhanced MRI and machine learning.

Crimi A, Commowick O, Maarouf A, Ferré JC, Bannier E, Tourbah A, Berry I, Ranjeva JP, Edan G, Barillot C.

PLoS One. 2014 Apr 1;9(4):e93024. doi: 10.1371/journal.pone.0093024. eCollection 2014.

34.

Brain networks disconnection in early multiple sclerosis cognitive deficits: an anatomofunctional study.

Louapre C, Perlbarg V, García-Lorenzo D, Urbanski M, Benali H, Assouad R, Galanaud D, Freeman L, Bodini B, Papeix C, Tourbah A, Lubetzki C, Lehéricy S, Stankoff B.

Hum Brain Mapp. 2014 Sep;35(9):4706-17. doi: 10.1002/hbm.22505. Epub 2014 Mar 31.

PMID:
24687771
35.

Switching from natalizumab to fingolimod in multiple sclerosis: a French prospective study.

Cohen M, Maillart E, Tourbah A, De Sèze J, Vukusic S, Brassat D, Anne O, Wiertlewski S, Camu W, Courtois S, Ruet A, Debouverie M, Le Page E, Casez O, Heinzlef O, Stankoff B, Bourre B, Castelnovo G, Rico A, Berger E, Camdessanche JP, Defer G, Clavelou P, Al Khedr A, Zephir H, Fromont A, Papeix C, Brochet B, Pelletier J, Lebrun C; Club Francophone de la Sclérose en Plaques Investigators.

JAMA Neurol. 2014 Apr;71(4):436-41. doi: 10.1001/jamaneurol.2013.6240.

PMID:
24566807
36.

Treatment effect on brain atrophy correlates with treatment effect on disability in multiple sclerosis.

Gout O, Tourbah A.

Ann Neurol. 2014 Mar;75(3):463. doi: 10.1002/ana.24112. Epub 2014 Feb 24. No abstract available.

PMID:
24493555
37.

[Progressive multifocal leukoencephalopathy and natalizumab-related immune reconstitution inflammatory syndrome: the advantage of MRI].

Gibelin N, Daelman L, Goulipian S, Wynckel A, Chaunu MP, Tourbah A.

Rev Neurol (Paris). 2014 Jan;170(1):48-50. doi: 10.1016/j.neurol.2013.03.009. Epub 2013 Oct 17. French. No abstract available.

PMID:
24139244
38.

A prospective observational post-marketing study of natalizumab-treated multiple sclerosis patients: clinical, radiological and biological features and adverse events. The BIONAT cohort.

Outteryck O, Ongagna JC, Brochet B, Rumbach L, Lebrun-Frenay C, Debouverie M, Zéphir H, Ouallet JC, Berger E, Cohen M, Pittion S, Laplaud D, Wiertlewski S, Cabre P, Pelletier J, Rico A, Defer G, Derache N, Camu W, Thouvenot E, Moreau T, Fromont A, Tourbah A, Labauge P, Castelnovo G, Clavelou P, Casez O, Hautecoeur P, Papeix C, Lubetzki C, Fontaine B, Couturier N, Bohossian N, Clanet M, Vermersch P, de Sèze J, Brassat D; BIONAT Network,; CFSEP.

Eur J Neurol. 2014;21(1):40-8. doi: 10.1111/ene.12204. Epub 2013 Jun 12.

PMID:
23895407
39.

POLG mutations associated with remitting/relapsing neurological events.

Degos B, Laforêt P, Jardel C, Sedel F, Jossay-Winter M, Romero NB, Lyon-Caen O, Tourbah A.

J Clin Neurosci. 2014 Jan;21(1):186-8. doi: 10.1016/j.jocn.2013.03.019. Epub 2013 Jul 2.

PMID:
23830586
40.

Acute disseminated encephalomyelitis in two renal transplant patients: is there a role for Epstein-Barr virus reactivation?

Caucheteux N, Maarouf A, Daelman L, Toupance O, Lavaud S, Tourbah A.

Mult Scler. 2013 Aug;19(9):1222-5. doi: 10.1177/1352458513478674. Epub 2013 Feb 28.

PMID:
23449733
41.

LSN MS guidelines for the management of multiple sclerosis.

Shatila AR, Koussa S, Jabbour R, Mourad A, Aouad A, Sabbagh G, Kallab K, Hilal R, Khalifeh R, Gebeily S, Tourbah A; Lebanese Society of Neurology.

Rev Neurol (Paris). 2013 Dec;169(12):950-5. doi: 10.1016/j.neurol.2012.12.002. Epub 2013 Feb 19. Review.

PMID:
23434141
42.

Contribution of imaging to the diagnosis of optic neuropathies.

Tourbah A.

Rev Neurol (Paris). 2012 Oct;168(10):702-5. doi: 10.1016/j.neurol.2012.07.012. Epub 2012 Sep 13. Review.

PMID:
22981271
43.

Severe multiple sclerosis reactivation under fingolimod 3 months after natalizumab withdrawal.

Daelman L, Maitrot A, Maarouf A, Chaunu MP, Papeix C, Tourbah A.

Mult Scler. 2012 Nov;18(11):1647-9. doi: 10.1177/1352458512458009. Epub 2012 Aug 20.

PMID:
22907938
44.

[Optical coherence tomography in neuro-ophthalmology].

Garcia T, Tourbah A, Setrouk É, Ducasse A, Arndt C.

J Fr Ophtalmol. 2012 Jun;35(6):454-66. doi: 10.1016/j.jfo.2012.02.002. Epub 2012 Jun 5. Review. French.

45.

Social cognition impairments in relapsing-remitting multiple sclerosis.

Henry A, Tourbah A, Chaunu MP, Rumbach L, Montreuil M, Bakchine S.

J Int Neuropsychol Soc. 2011 Nov;17(6):1122-31. doi: 10.1017/S1355617711001147. Epub 2011 Oct 7.

PMID:
22014035
46.

Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis.

International Multiple Sclerosis Genetics Consortium; Wellcome Trust Case Control Consortium 2, Sawcer S, Hellenthal G, Pirinen M, Spencer CC, Patsopoulos NA, Moutsianas L, Dilthey A, Su Z, Freeman C, Hunt SE, Edkins S, Gray E, Booth DR, Potter SC, Goris A, Band G, Oturai AB, Strange A, Saarela J, Bellenguez C, Fontaine B, Gillman M, Hemmer B, Gwilliam R, Zipp F, Jayakumar A, Martin R, Leslie S, Hawkins S, Giannoulatou E, D'alfonso S, Blackburn H, Martinelli Boneschi F, Liddle J, Harbo HF, Perez ML, Spurkland A, Waller MJ, Mycko MP, Ricketts M, Comabella M, Hammond N, Kockum I, McCann OT, Ban M, Whittaker P, Kemppinen A, Weston P, Hawkins C, Widaa S, Zajicek J, Dronov S, Robertson N, Bumpstead SJ, Barcellos LF, Ravindrarajah R, Abraham R, Alfredsson L, Ardlie K, Aubin C, Baker A, Baker K, Baranzini SE, Bergamaschi L, Bergamaschi R, Bernstein A, Berthele A, Boggild M, Bradfield JP, Brassat D, Broadley SA, Buck D, Butzkueven H, Capra R, Carroll WM, Cavalla P, Celius EG, Cepok S, Chiavacci R, Clerget-Darpoux F, Clysters K, Comi G, Cossburn M, Cournu-Rebeix I, Cox MB, Cozen W, Cree BA, Cross AH, Cusi D, Daly MJ, Davis E, de Bakker PI, Debouverie M, D'hooghe MB, Dixon K, Dobosi R, Dubois B, Ellinghaus D, Elovaara I, Esposito F, Fontenille C, Foote S, Franke A, Galimberti D, Ghezzi A, Glessner J, Gomez R, Gout O, Graham C, Grant SF, Guerini FR, Hakonarson H, Hall P, Hamsten A, Hartung HP, Heard RN, Heath S, Hobart J, Hoshi M, Infante-Duarte C, Ingram G, Ingram W, Islam T, Jagodic M, Kabesch M, Kermode AG, Kilpatrick TJ, Kim C, Klopp N, Koivisto K, Larsson M, Lathrop M, Lechner-Scott JS, Leone MA, Leppä V, Liljedahl U, Bomfim IL, Lincoln RR, Link J, Liu J, Lorentzen AR, Lupoli S, Macciardi F, Mack T, Marriott M, Martinelli V, Mason D, McCauley JL, Mentch F, Mero IL, Mihalova T, Montalban X, Mottershead J, Myhr KM, Naldi P, Ollier W, Page A, Palotie A, Pelletier J, Piccio L, Pickersgill T, Piehl F, Pobywajlo S, Quach HL, Ramsay PP, Reunanen M, Reynolds R, Rioux JD, Rodegher M, Roesner S, Rubio JP, Rückert IM, Salvetti M, Salvi E, Santaniello A, Schaefer CA, Schreiber S, Schulze C, Scott RJ, Sellebjerg F, Selmaj KW, Sexton D, Shen L, Simms-Acuna B, Skidmore S, Sleiman PM, Smestad C, Sørensen PS, Søndergaard HB, Stankovich J, Strange RC, Sulonen AM, Sundqvist E, Syvänen AC, Taddeo F, Taylor B, Blackwell JM, Tienari P, Bramon E, Tourbah A, Brown MA, Tronczynska E, Casas JP, Tubridy N, Corvin A, Vickery J, Jankowski J, Villoslada P, Markus HS, Wang K, Mathew CG, Wason J, Palmer CN, Wichmann HE, Plomin R, Willoughby E, Rautanen A, Winkelmann J, Wittig M, Trembath RC, Yaouanq J, Viswanathan AC, Zhang H, Wood NW, Zuvich R, Deloukas P, Langford C, Duncanson A, Oksenberg JR, Pericak-Vance MA, Haines JL, Olsson T, Hillert J, Ivinson AJ, De Jager PL, Peltonen L, Stewart GJ, Hafler DA, Hauser SL, McVean G, Donnelly P, Compston A.

Nature. 2011 Aug 10;476(7359):214-9. doi: 10.1038/nature10251.

47.

Dramatic worsening following plasma exchange in severe post-natalizumab withdrawal multiple sclerosis relapse.

Papeix C, Depaz R, Tourbah A, Stankoff B, Lubetzki C.

Mult Scler. 2011 Dec;17(12):1520-2. doi: 10.1177/1352458511411064. Epub 2011 Jun 13.

PMID:
21669937
48.

[NeuroBehcet disease with corpus callosum involvement].

Maarouf A, Hadj-Henni L, Caucheteux N, Renkes C, Serre I, Bakchine S, Tourbah A.

Rev Neurol (Paris). 2011 Jun-Jul;167(6-7):533-6. doi: 10.1016/j.neurol.2010.10.010. Epub 2011 Mar 21. French.

PMID:
21420702
49.

Binucleated lymphocytes in patients with multiple sclerosis treated with natalizumab.

Leclerc M, Lesesve JF, Gaillard B, Troussard X, Tourbah A, Debouverie M, Daliphard S, Delmer A.

Leuk Lymphoma. 2011 May;52(5):910-2. doi: 10.3109/10428194.2010.551156. Epub 2011 Feb 14. No abstract available.

PMID:
21314485
50.

Cancer and multiple sclerosis in the era of disease-modifying treatments.

Lebrun C, Vermersch P, Brassat D, Defer G, Rumbach L, Clavelou P, Debouverie M, de Seze J, Wiertlevsky S, Heinzlef O, Tourbah A, Fromont A, Frenay M.

J Neurol. 2011 Jul;258(7):1304-11. doi: 10.1007/s00415-011-5929-9. Epub 2011 Feb 4.

PMID:
21293872

Supplemental Content

Loading ...
Support Center